Here’s what you should know:
1. Bayer challenged the necessity of the label but dropped its challenge after several Iberogast users reported liver damage..
2. The label advises people who have liver disease or are pregnant or breastfeeding to avoid the drug.
3. Bayer said more than 82 million patients have used Iberogast since its launch.
More articles on gastroenterology:
Mackinaw Surgery Center recognized by SPH Analytics — 3 insights
5 must-read articles for GI physicians this week: Sept. 6-12
How one ASC reduced infection rates while adding total joint procedures
